GLENMARK PHARMA RECEIVES U.S. FDA EIR FOR GOA FACILITY

• The company has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India. • The facility has received a Voluntary Action Indicated (VAI) status. • The inspection was conducted from June 22, 2026, to June 30, 2026.

Glenmark Pharmaceuticals Limited

Open attachment

← Back to feed